ClinConnect ClinConnect Logo
Search / Trial NCT01381757

Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Jun 23, 2011

Trial Information

Current as of May 06, 2025

Terminated

Keywords

Extensively Drug Resistant Tuberculosis First Line Antituberculous Drugs Second Line Antituberculous Drugs Middlebrook Culture Agar Proportion Method

ClinConnect Summary

Approximately one-third of the world s population is infected with tuberculosis (TB), and over 1 million deaths occur annually worldwide because of it (1,2). Accurate diagnosis and TB drug susceptibility testing is necessary to treat the infection appropriately and bring this epidemic under control. Inappropriate treatment of TB, on the other hand, has led to the recent spread in multidrug-resistant TB (MDR-TB), estimated to affect over half of million people worldwide (2,4,5). Sputum smear microscopy, the diagnostic method commonly used in developing countries, is not as sensitive at detec...

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • Individuals (12 years of age) who meet the following criteria are eligible for enrollment in the study:
  • Have a sputum smear that is positive for acid-fast bacilli by microscopy or have clinical symptoms and abnormal findings compatible with active TB on a previously performed chest radiograph.
  • Have either completed at least 5 months of treatment with antituberculous therapy within the past year or have not received any antituberculous treatment in the preceding 5 years.
  • Willingness to provide a sputum sample for the study.
  • Ability to follow verbal instructions for producing sputum.
  • Willingness to undergo testing for HIV.
  • Willingness to allow storage of samples for future research.
  • EXCLUSION CRITERIA:
  • Subjects who meet any of the following criteria are not eligible for enrollment in the study:
  • Any condition that in the investigator s opinion places the subject at undue risk by participating in the study.
  • Subjects younger than 12 years of age will be excluded from the study due to the difficulty of obtaining adequate sputum samples for the diagnosis of TB in this population and because there are no means for obtaining gastric aspirates at the reference centers.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Bethesda, Maryland, United States

Bamako, , Mali

Patients applied

0 patients applied

Trial Officials

Sophia B Siddiqui, M.D.

Principal Investigator

National Institute of Allergy and Infectious Diseases (NIAID)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials